SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-051383
Filing Date
2024-05-01
Accepted
2024-05-01 17:04:58
Documents
13
Period of Report
2024-04-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20240425.htm   iXBRL 8-K 59646
2 EX-10.1 aktx-ex10_1.htm EX-10.1 17260
3 EX-99.1 aktx-ex99_1.htm EX-99.1 41857
  Complete submission text file 0000950170-24-051383.txt   359455

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20240425.xsd EX-101.SCH 97461
16 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20240425_htm.xml XML 6055
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 24903955
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)